Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

EXIT-CVD Exit-cvd

Coordinator
Academisch Ziekenhuis Groningen, Netherlands
Runs
1 April 2026 to 31 March 2031
Status
Running
EU funding
€15.2m
Total cost
€27.7m
Partners
43 organisations in 17 countries
Type
Research and Innovation Action
Grant agreement
101253160

What the project is doing

In the project's own words, from its summary on CORDIS.

EXIT-CVD aims to fundamentally transform cardiovascular disease (CVD) management by enabling early, personalized, and equitable interventions across the CVD continuum. Recognizing CVD as a dynamic progression, from risk factors to heart failure and premature death, EXIT-CVD identifies and operationalizes strategic ""exit points"" where disease trajectories can be disrupted. Through a multidisciplinary, public-private partnership involving academia, Medtech, pharma, SMEs, and patient organizations, the project will integrate state-of-the-art diagnostics (e.g., photon-counting CT, AI-enhanced wearables), digital monitoring, regenerative therapies, and advanced imaging-guided interventions.

Innovations are embedded in a digitally enabled, FAIR-compliant data platform aligned with the European Health Data Space (EHDS), ensuring real-world scalability and regulatory readiness. EXIT-CVD rigorously applies implementation science through the frameworks RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) which evaluates interventions along five core dimensions relevant to health systems uptake, and PROCTOR (Implementation Outcomes Framework) which focuses on concrete metrics such as acceptability, feasibility, fidelity, and cost.

Additionally, EXIT-CVD adopts an equity-by-design approach to overcome persistent health disparities. Clinical studies target early detection (e.g., wearable blood pressure and AI-Electrocardiogram monitoring), intermediate stratification (e.g., imaging-guided Percutaneous Coronary Intervention (PCI) with Photon-Counting Computed Tomography (PCCT)), and late-stage recovery (e.g., engineered heart muscle transplantation and minimally invasive cardiac surgery supported by mechanical circulatory devices).

By co-creating with patients and systematically addressing socioeconomic, gender, and digital access gaps, EXIT-CVD envisions a future where heart disease is not a terminal continuum but a preventable and reversible condition. This project will deliver validated, sustainable, and equitable innovations, positioning Europe at the forefront of cardiovascular health transformation.""

Topics

Who is involved

OrganisationCityCountryRole
Academisch Ziekenhuis GroningenGroningenNetherlandsCoordinator
Katholieke Universiteit LeuvenLeuvenBelgiumParticipant
Circle Cardiovascular Imaging Inc.CalgaryCanadaParticipant
Bgp Products Operations GmbHSteinhausenSwitzerlandParticipant
Ente Ospedaliero CantonaleBellinzonaSwitzerlandParticipant
Abiomed Europe GmbHAachenGermanyParticipant
Klinikum Der Universitaet Zu KoelnKoelnGermanyParticipant
Philips GmbHHamburgGermanyParticipant
Repairon GmbHGottingenGermanyParticipant
Sanofi-Aventis Deutschland GmbHFrankfurt Am MainGermanyParticipant
Siemens Healthineers AGForchheimGermanyParticipant
Zoll Cms GmbHKolnGermanyParticipant
Bridg OuTallinEstoniaParticipant
Fundacio De Gestio Sanitaria De L'hospital De La Santa Creu I Sant PauBarcelonaSpainParticipant
Medtronic Iberica SAMadridSpainParticipant
Huawei Technologies Oy (finland) Co LtdHelsinkiFinlandParticipant
Varsinais-Suomen HyvinvointialueTurkuFinlandParticipant
Societe Europeenne De CardiologieBiotFranceParticipant
Megi Health d.o.o.ZagrebCroatiaParticipant
Centro Cardiologico MonzinoMilanoItalyParticipant
Politecnico Di MilanoMilanoItalyParticipant
Universita Degli Studi Di PaviaPaviaItalyParticipant
Corbotics B.V.DelftNetherlandsParticipant
Cordys Analytics B.V.UtrechtNetherlandsParticipant
Iqvia Solutions B.v.AmsterdamNetherlandsParticipant
Johnson & Johnson Medical B.v.AmersfoortNetherlandsThird party
Novartis Pharma B.V.AmsterdamNetherlandsParticipant
Philips Electronics Nederland BVEindhovenNetherlandsParticipant
Philips Nederland BVEindhovenNetherlandsParticipant
Stichting VrouwenHartLeidschendamNetherlandsParticipant
Technische Universiteit EindhovenEindhovenNetherlandsParticipant
Universitair Medisch Centrum UtrechtUtrechtNetherlandsParticipant
Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego - Panstwowy Instytut BadawczyWarszawaPolandParticipant
Cardio Med SRLTargu MuresRomaniaParticipant
Astrazeneca ABSodertaeljeSwedenParticipant
Xvivo Perfusion AktiebolagGoteborgSwedenParticipant
Huawei Telekomünikasyon Dis Ticaret Limited SirketiİstanbulTürkiyeParticipant
Cogstack LimitedHadlowUnited KingdomParticipant
King's College LondonLondonUnited KingdomParticipant
London School of Economics and Political ScienceLondonUnited KingdomParticipant
Onsentia LimitedHadlow KentUnited KingdomParticipant
Ge Precision Healthcare LlcWilmingtonUnited StatesParticipant
Heartbeam IncSanta ClaraUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI